ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015
[The relationship between WT1 expression level and prognosis in patients of acute T lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo probe monitoring Wilms tumor-1（WT1）gene expression level in acute T lymphoblastic leukemia（T- ALL）following allogeneic hematopoietic stem cell transplantation（allo-HSCT）with prognostic significance.
methodsThis retrospective study analyzed 68 T-ALL cases from January 2009 to March 2012, that monitoring WT1 gene expression level after allo-HSCT. WT1 expression level was measured with real-time quantitative reverse transcription polymerase chain reaction（RQ-PCR） method at + 30, + 60, + 90, + 180, + 270, + 360 days after allo-HSCT, simultaneously monitoring residual leukemia using flow cytometry（FCM）.
resultsLow WT1 gene expression level associated with a low risk of recurrence after allo-HSCT in T-ALL. Increased WT1 gene expression levels at +60 and + 90 days after allo- HSCT associated with higher cumulative incidences of relapse（P<0.001, P=0.003）, and low disease- free survival rates（P=0.004, P=0.006）, and low overall survival rates（P=0.004, P=0.007）. The presence of MRD after allo-HSCT was an independent prognostic factor for relapse in T-ALL. Combining WT1 gene and FCM could be used to monitor recurrence after allo-HSCT.
conclusionIncreased WT1 gene expression level at +60 and + 90 days after allo-HSCT significantly associated with worse prognosis, that should be intervened as early as possible to reduce the risk of recurrence or death. WT1 gene expression level that was less than 0.6% associated with lower risk of recurrence. WT1 gene expression more than 0.6% that needed close follow- up, combined with FCM monitoring MRD, which required intervention to reduce the relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.